• Explore /
  • Poster
  • / Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with <em>ALK</em>+ advanced non–small cell lung cancer (NSCLC).

Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).

Abstract Video & Slides Poster

Authors

null

Benjamin J. Solomon

Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre & Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia

Benjamin J. Solomon , Todd Michael Bauer , Enriqueta Felip , Geoffrey Liu , Julien Mazieres , Filippo de Marinis , Yasushi Goto , Dong-Wan Kim , Konstantin K. Laktionov , Fiona Helen Blackhall , Elisa Dall’O , Anna Polli , Francesca Toffalorio , Tony S. K. Mok

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03052608

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9069)

DOI

10.1200/JCO.2022.40.16_suppl.9069

Abstract #

9069

Poster Bd #

56

Abstract Disclosures

Similar Posters

First Author: Todd Michael Bauer

First Author: Alessandra Bearz

First Author: Hongyun Zhao

First Author: Simon Baldacci